Arterial calcification is driven by RAGE in enpp1-/-mice

Journal of Vascular Research

Volumn 48, Issue 3, 2011, Pages 227-235

  Cecil, Denise L ^a   Terkeltaub, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Artery calcification; Calgranulin; ENPP1; Pit 1; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; COLLAGEN TYPE 11; COLLAGEN TYPE 9; PROTEIN; PROTEIN ENPP1; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTERY CALCIFICATION; ARTICLE; CHONDROGENESIS; CONTROLLED STUDY; EXPLANT; GENE EXPRESSION; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE DIFFERENTIATION;

ALKALINE PHOSPHATASE; ANIMALS; AORTA; AORTIC DISEASES; CALCINOSIS; CHONDROGENESIS; COLLAGEN TYPE IX; COLLAGEN TYPE XI; DISEASE MODELS, ANIMAL; GENOTYPE; LIGANDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; PHENOTYPE; PHOSPHATES; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS;

EID: 78449238727     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318805     Document Type: Article

References (52)

1. Demer LL, Tintut Y: Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117: 2938-2948. (Pubitemid 351787058)
2. Shao JS, Cai J, Towler DA: Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006; 26: 1423-1430. (Pubitemid 44288965)
3. El-Abbadi M, Giachelli CM: Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 54-66. (Pubitemid 46014536)
4. Rutsch F, Ruf N, Vaingankar S, Toliat MR Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nürnberg P: Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003; 34: 379-381. (Pubitemid 36935330)
5. Abedin M, Tintut Y, Demer LL: Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-1170. (Pubitemid 38880003)
6. Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, Neumann M, Shanahan CM, Proudfoot D: Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103:28-34.
7. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA: Aortic Msx2-Wnt calcification cascade is regulated by TNF-a-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Bio 2007;27:2589-2596. (Pubitemid 350158910)
8. Johnson KA, Polewski M, Terkeltaub RA: Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res 2008; 102: 529-537. (Pubitemid 351416752)
9. El-Maadawy S, Kaartinen MT, Schinke T, Murshed M, Karsenty G, McKee MD: Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res 2003; 44(suppl 1):272-278. (Pubitemid 36395456)
10. Murshed M, Harmey D, Millán JL, McKee M D, Ka rs ent y G : Un ique coexpres sion in os-teoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19: 1093-1104. (Pubitemid 40632454)
11. Li X, Yang HY, Giachelli CM: Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98:905-912.
12. Johnson KA, Yao W, Lane NE, Naquet P, Ter-keltaub RA: Vanin-1 pantetheinase drives increased chondrogenic potential of mesen-chymal precursors in ank/ank mice. Am J Pathol 2008; 172 : 440-453. (Pubitemid 351282031)
13. i depletion promotes spontaneous aortic calcification in NPP1-/-mice. Arterioscler Thromb Vasc Biol 2005; 25:686-691. (Pubitemid 40463854)
14. Rutsch F, Böyer P, Nitschke Y, Ruf N, Lorenz-Deperieux B, Wittkampf T, Weissen-Plenz G, Mughal Z, Gregory J, Davies J, Loirat C, S t ro m T, Sch n abel D, Nü r nberg P, Terkelt au b R; and the GACI Study Group: Hypophos-phatemia, hyperphosphaturia and bisphos-phonate treatment are associated with sur-vival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet 2008; 1: 133-140.
15. Lorenz-Depiereux B, Schnabel D, Tiosano D, Häusler G, Strom TM: Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010; 86: 267-272.
16. Levy-Litan V, Hershkovitz E, Avizov L, Le-venthal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R: Autosomal-recessive hypophos-phatemic rickets is associated with an inac-tivation mutation in the ENPP1 gene. Am J Hum Genet 2010; 86:273-278.
17. Spiekerkoetter E, Guignabert C, de Jesus Perez V, Alastalo TP, Powers JM, Wang L, Lawrie A, Ambartsumian N, Schmidt AM, Berryman M, Ashley RH, Rabinovitch M: S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracel-lular signal-regulated kinase and chloride intracellular channel 4. Circ Res 2009; 105: 639-647.
18. Heizmann CW, Ackermann GE, Galichet A: Pathologies involving the S100 proteins and RAGE. Subcell Biochem 2007; 45:93-138.
19. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM: Receptor for advanced glyca-tion end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann NY Acad Sci 2008; 1126: 7-13. (Pubitemid 351589318)
20. Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008; 4:285-293. (Pubitemid 351571138)
21. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bier-haus A, Cooper ME, Jandeleit-Dahm KA: Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57: 2461-2469.
22. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ra-masamy R, Yan SF, Schmidt AM: Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J Clin Invest 2008; 118 : 183-194 .
23. Cecil DL, Terkeltaub R: Transamidation by transglutaminase 2 transforms S100A11 cal-granulin into a procatabolic cytokine for chondrocy tes. J Immunol 2008; 180 : 8378-8385.
24. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R: Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol 2005; 175:8296-8302. (Pubitemid 41798395)
25. Ya mag ishi S, Fuji mor i H, Yonek u r a H, Ta n a-ka N, Yamamoto H: Advanced glycation endproducts accelerate calcification in mi-crovascular pericytes. Biochem Biophys Res Commun 1999; 258:353-357. (Pubitemid 29287055)
26. Ren X, Shao H, Wei Q, Sun Z, Liu N: Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 2009; 37: 847-854.
27. Tan ikawa T, Okada Y, Tani kawa R, Tana ka Y: Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009; 46: 572-580.
28. Galichet A, Weibel M, Heizmann CW: Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun 2008; 370 : 1-5 .
29. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glyca-tion endproducts. Nat Med 1998; 4:1025-1031. (Pubitemid 28417334)
30. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22:3716-3727.
31. Basta G, Corciu AI, Vianello A, Del Turco S, Foffa I, Navarra T, Chiappino D, Berti S, Mazzone A: Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis 2010 [Epub ahead of print].
32. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS: Calcium-dependent and-independent interactions of the S100 protein family. Biochem J 2006; 396: 201-214. (Pubitemid 43837235)
33. Shimamoto S, Takata M, Tokuda M, Oohira F, Tokumitsu H, Kobayashi R: Interactions of S100A2 and S100A6 with the tetratricopep-tide repeat proteins, Hsp90/Hsp70-organiz-ing protein and kinesin light chain. J Biol Chem 2008; 283:28246-28258.
34. Donato R: RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 2007; 7: 711-724.
35. Yammani RR, Carlson CS, Bresnick AR, Loeser RF: Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced gly-cation end products. Arthritis Rheum 2006; 54:2901-2911. (Pubitemid 44497769)
36. Wolff DA, Stevenson S, Goldberg VM: S-100 protein immunostaining identifies cells expressing a chondrocytic phenotype during articular cartilage repair. J Orthop Res 1992; 10:49-57.
37. i and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003; 18 : 994-1004. (Pubitemid 37294935)
38. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S: Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998; 19: 271-273. (Pubitemid 28309341)
39. Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R: Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum 2005; 52:144-154. (Pubitemid 40129243)
40. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA, Demer LL: Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in os-teoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17:680-687. (Pubitemid 27169128)
41. Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, Nawroth P, Stern DM, Xiong WC: Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203:1067-1080.
42. Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B, Yan SL, She JX, Stern DM, Isales CM, Mi QS: Disordered osteo-clast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 2006; 340:1091-1097. (Pubitemid 43083390)
43. Towler DA, Shao JS, Cheng SL, Pingsterhaus JM, Loewy AP: Osteogenic regulation of vascular calcification. Ann NY Acad Sci 2006; 1068:327-333. (Pubitemid 43824164)
44. Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, Nawroth PP, Katus HA, Remppis A: Increased proinf lammatory endothelial response to S100A8/A9 after pre-activation through advanced glycation end products. Cardiovasc Diabetol 2006; 5:6.
45. Reddy MA, Li SL, Sahar S, Kim YS, Xu ZG, Lanting L, Natarajan R: Key role of Src ki-nase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cel ls. J Biol Chem 2006; 281: 13685-13693. (Pubitemid 43855284)
46. Bobryshev YV, Babaev VR, Iwasa S, Lord RS, Watanabe T: Atherosclerotic lesions of apo-lipoprotein E deficient mice contain cells expressing S100 protein. Atherosclerosis 1999; 143:451-454. (Pubitemid 29166928)
47. Bobryshev YV, Lord RS: S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res 1995; 29:689-696.
48. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007; 16 : 136-143. (Pubitemid 46729668)
49. Cecil DL, Appleton CT, Polewski MD, Mort JS, Schmidt AM, Bendele A, Beier F, Terkel-taub R: The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli. J Immunol 2009; 182 : 5024-5031.
50. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR: Elas-tin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110: 3480-3487. (Pubitemid 39602227)
51. Qin X, Corriere MA, Matrisian LM, Guzman RJ: Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol 2006; 26: 1510-1516. (Pubitemid 44288976)
52. Englert JM, Hanford LE, Kaminski N, Tobo-lewski JM, Tan RJ, Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP, Kasper M, Bierhaus A, Oury TD: A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pat hol 2008; 172 : 583-591. (Pubitemid 351354532)